...
atyr-img

aTyr Pharma, Inc., Common Stock

ATYR

NAQ

$3.124

-$0.03

(-0.95%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$144.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
462.88K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.21
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.34 L
$3.8 H
$3.124

About aTyr Pharma, Inc., Common Stock

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameATYRSectorS&P500
1-Week Return-0.63%-3.39%-3.47%
1-Month Return4.65%-3.25%-0.29%
3-Month Return73.08%-11.61%4.5%
6-Month Return90.91%-5.89%6.91%
1-Year Return148.03%2.65%23.79%
3-Year Return-60.33%0.56%28.43%
5-Year Return-20.45%34.63%83.64%
10-Year Return-98.49%94.78%185.94%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue10.46M-10.39M353.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":99.34,"profit":true},{"date":"2023-12-31","value":3.38,"profit":true}]
Cost of Revenue17.29M1.30M1.70M2.74M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":7.54,"profit":true},{"date":"2022-12-31","value":9.8,"profit":true},{"date":"2023-12-31","value":15.85,"profit":true}]
Gross Profit(6.84M)(1.30M)8.69M(2.39M)[{"date":"2020-12-31","value":-78.66,"profit":false},{"date":"2021-12-31","value":-15,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-27.48,"profit":false}]
Gross Margin(65.38%)(Infinity%)83.68%(676.49%)[{"date":"2020-12-31","value":-78.14,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-808.42,"profit":false}]
Operating Expenses25.10M32.71M55.09M55.27M[{"date":"2020-12-31","value":45.41,"profit":true},{"date":"2021-12-31","value":59.18,"profit":true},{"date":"2022-12-31","value":99.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(15.91M)(34.02M)(46.40M)(54.92M)[{"date":"2020-12-31","value":-1591100000,"profit":false},{"date":"2021-12-31","value":-3401500000,"profit":false},{"date":"2022-12-31","value":-4640400000,"profit":false},{"date":"2023-12-31","value":-5491900000,"profit":false}]
Total Non-Operating Income/Expense----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(16.23M)(33.78M)(45.34M)(50.40M)[{"date":"2020-12-31","value":-1623000000,"profit":false},{"date":"2021-12-31","value":-3377700000,"profit":false},{"date":"2022-12-31","value":-4534300000,"profit":false},{"date":"2023-12-31","value":-5039700000,"profit":false}]
Income Taxes(6.00K)(9.00K)(5.00K)(8.00K)[{"date":"2020-12-31","value":-600000,"profit":false},{"date":"2021-12-31","value":-900000,"profit":false},{"date":"2022-12-31","value":-500000,"profit":false},{"date":"2023-12-31","value":-800000,"profit":false}]
Income After Taxes----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(16.23M)(33.78M)(45.34M)(50.40M)[{"date":"2020-12-31","value":-1623000000,"profit":false},{"date":"2021-12-31","value":-3377700000,"profit":false},{"date":"2022-12-31","value":-4534300000,"profit":false},{"date":"2023-12-31","value":-5039700000,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(16.22M)(33.77M)(45.34M)(50.39M)[{"date":"2020-12-31","value":-1622400000,"profit":false},{"date":"2021-12-31","value":-3376800000,"profit":false},{"date":"2022-12-31","value":-4533800000,"profit":false},{"date":"2023-12-31","value":-5038900000,"profit":false}]
EPS (Diluted)(1.58)(1.88)(1.60)(0.96)[{"date":"2020-12-31","value":-158.46,"profit":false},{"date":"2021-12-31","value":-188.15,"profit":false},{"date":"2022-12-31","value":-159.99,"profit":false},{"date":"2023-12-31","value":-95.89,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ATYR
Cash Ratio 4.67
Current Ratio 5.41

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ATYR
ROA (LTM) -32.74%
ROE (LTM) -61.76%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ATYR
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ATYR
Trailing PE NM
Forward PE NM
P/S (TTM) 244.92
P/B 1.76
Price/FCF NM
EV/R 135.00
EV/Ebitda NM

FAQs

What is aTyr Pharma, Inc. share price today?

aTyr Pharma, Inc. (ATYR) share price today is $3.124

Can Indians buy aTyr Pharma, Inc. shares?

Yes, Indians can buy shares of aTyr Pharma, Inc. (ATYR) on Vested. To buy aTyr Pharma, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATYR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of aTyr Pharma, Inc. be purchased?

Yes, you can purchase fractional shares of aTyr Pharma, Inc. (ATYR) via the Vested app. You can start investing in aTyr Pharma, Inc. (ATYR) with a minimum investment of $1.

How to invest in aTyr Pharma, Inc. shares from India?

You can invest in shares of aTyr Pharma, Inc. (ATYR) via Vested in three simple steps:

  • Click on Sign Up or Invest in ATYR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in aTyr Pharma, Inc. shares
What is aTyr Pharma, Inc. 52-week high and low stock price?

The 52-week high price of aTyr Pharma, Inc. (ATYR) is $3.8. The 52-week low price of aTyr Pharma, Inc. (ATYR) is $1.34.

What is aTyr Pharma, Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of aTyr Pharma, Inc. (ATYR) is

What is aTyr Pharma, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of aTyr Pharma, Inc. (ATYR) is 1.76

What is aTyr Pharma, Inc. dividend yield?

The dividend yield of aTyr Pharma, Inc. (ATYR) is 0.00%

What is the Market Cap of aTyr Pharma, Inc.?

The market capitalization of aTyr Pharma, Inc. (ATYR) is $144.01M

What is aTyr Pharma, Inc.’s stock symbol?

The stock symbol (or ticker) of aTyr Pharma, Inc. is ATYR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top